GlassScriptPhysician profile
Sacara D Shaw
NPI 1528215225
$9,242.24
in general payments reported to CMS, 2019-2025
38 companies · $4,123 in 2025
The $4,123 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $143 · 2021: $940 · 2022: $755 · 2023: $767 · 2024: $2,150 · 2025: $4,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $2,040.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $5,000.00 | 2024-2025 | Bovine Collagen |
| Aspira Women'S Health INC | $638.26 | 2021-2024 | Ova1 |
| Abbvie INC. | $602.41 | 2019-2024 | Lo Loestrin Fe |
| Coopersurgical, INC. | $442.27 | 2019-2025 | Endosee, Summit Doppler, Paragard T 380a |
| Medtronic, INC. | $428.56 | 2021-2024 | Axium Primetm, Solitaire X, Rist |
| Bayer Healthcare Pharmaceuticals INC. | $314.57 | 2019-2025 | |
| Astellas Pharma US INC | $267.48 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $246.24 | 2021-2025 | |
| Biogen, INC. | $174.51 | 2024-2025 | Zurzuvae |
| Organon LLC | $135.03 | 2022-2024 | Nexplanon |
| Sumitomo Pharma America, INC. | $97.75 | 2025 | Myfembree |
| Exeltis, USA INC. | $90.30 | 2020-2025 | Slynd |
| Agile Therapeutics, INC. | $83.67 | 2021-2022 | |
| Millicent US INC | $81.62 | 2022-2025 | Intrarosa, Femlyv |
| Pfizer INC. | $81.28 | 2023-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $53.89 | 2020-2022 | |
| Channel Medsystems, INC. | $42.46 | 2024 | |
| Shield Therapeutics INC | $42.03 | 2023 | Accrufer |
| Duchesnay USA Incorporated | $39.19 | 2019 | |
| Allergan, INC. | $35.57 | 2019 | |
| Therapeuticsmd, INC. | $35.49 | 2021-2022 | |
| Ethicon US, LLC | $32.61 | 2022-2025 | Stratafix, Ethicon |
| Merck Sharp & Dohme LLC | $27.78 | 2019 | |
| Vertical Pharmaceuticals, LLC | $25.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $23.99 | 2019 | |
| Avion Pharmaceuticals | $22.12 | 2021 | |
| Octapharma USA, INC. | $18.76 | 2025 | Fibryga |
| Hologic Sales and Service, LLC | $17.95 | 2023 | Aptima |
| Roche Diagnostics Corporation | $16.11 | 2020 | |
| Lupin INC. | $16.10 | 2019 | |
| Exact Sciences Corporation | $15.65 | 2025 | Cologuard Collection Kit |
| Minerva Surgical, INC | $14.74 | 2019 | |
| Amgen INC. | $13.79 | 2020 | |
| Olympus America INC. | $13.54 | 2023 | Olympus |
| Boston Scientific Corporation | $13.20 | 2020 | |
| Meditrina | $12.92 | 2025 | |
| Scynexis, INC. | $12.76 | 2022 | |
| Evofem Biosciences, INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sacara Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.